Menichetti, Francesco · Journal of clinical medicine · 2023 · DOI
This article discusses how a treatment called hypothalamic phospholipid liposomes might help with ME/CFS and brain fog symptoms in people with Long COVID. These liposomes are small fatty particles that are already available as a supportive treatment for brain and hormone-related problems. The authors suggest this treatment could be helpful based on how it works and their early clinical experiences, though more rigorous testing is still needed.
This work addresses a critical clinical need in ME/CFS and Long COVID management, where effective treatments remain limited. By proposing a mechanistically plausible therapeutic approach grounded in the neuroendocrine and metabolic dysfunction underlying these conditions, it opens a potential avenue for symptom management that could improve quality of life for patients with ME/CFS and related post-viral conditions.
This editorial does not provide evidence from controlled clinical trials that hypothalamic phospholipid liposomes are effective for ME/CFS or Long COVID. The preliminary clinical experience mentioned is anecdotal rather than systematically collected, and the study does not establish causation or quantify treatment efficacy. This is theoretical speculation supported by mechanism, not proof of clinical benefit.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.